Cencora Inc. (COR) Stock
Key stats
- Market cap
- $64.82B
- Price / Earnings ratio
- 25.7x
- EPS (TTM)
- $13.52
- Volume
- Loading
- 52-week high
- $377.54
- 52-week low
- $244.82
- Dividend yield
- 0.71%
- Dividend amount (latest)
- $0.60
- EPS vs analyst estimate
- +1.3%Q4 FY25 · $3.84 vs $3.79
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with COR
Recent news

Why Cencora (COR) is a Top Growth Stock for the Long-Term
Why Cencora (COR) is a Top Growth Stock for the Long-Term
COR

Cencora Gears Up to Report Q4 Results: How to Play the Stock?
Cencora Gears Up to Report Q4 Results: How to Play the Stock?
COR

Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
COR

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
COR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.47
- MACD 12/26/9
- 5.13
- EMA 9 of MACD
- 4.38
- MACD histogram
- 0.74
- SMA 50
- $324.87
- Price above SMA 50
- EMA 50
- $325.90
- Price above EMA 50
- SMA 200
- $316.88
- Price above SMA 200
- EMA 200
- $324.27
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $4.38 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Why Cencora (COR) is a Top Growth Stock for the Long-Term
Why Cencora (COR) is a Top Growth Stock for the Long-Term
COR

Cencora Gears Up to Report Q4 Results: How to Play the Stock?
Cencora Gears Up to Report Q4 Results: How to Play the Stock?
COR

Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
COR

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
COR

Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
COR

Cencora to acquire American Oncology Network in $2.4 billion deal
Cencora to acquire American Oncology Network in $2.4 billion deal
COR

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
COR

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
COR

Cencora Elects Robert E. Sanchez to Its Board of Directors
Cencora Elects Robert E. Sanchez to Its Board of Directors
COR

Here's Why Cencora (COR) is a Strong Growth Stock
Here's Why Cencora (COR) is a Strong Growth Stock
COR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Cencora Inc.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert P. Mauch Ph.D., PharmD | President, CEO & Director | 1967 |
| Ms. Eva C. Boratto | Executive VP & CFO | 1967 |
| Ms. Elizabeth S. Campbell J.D. | Executive VP & Chief Legal Officer | 1975 |
| Mr. James F. Cleary Jr. | Advisor | 1963 |
| Ms. Silvana Battaglia | Advisor | 1968 |
| Mr. Lazarus Krikorian | Senior VP, Chief Accounting Officer & Corporate Controller | 1965 |
| Mr. Pawan Singh Verma | Executive VP and Chief Data & Information Officer | 1977 |
| Mr. Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury | — |
| Ms. Samantha L. Hammock | Executive VP & Chief Human Resources Officer | 1979 |
| Mr. Richard Tremonte | EVP and President of U.S. Pharmaceuticals & Animal Health | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 56.47
- MACD 12/26/9
- 5.13
- EMA 9 of MACD
- 4.38
- MACD histogram
- 0.74
- SMA 50
- $324.87
- Price above SMA 50
- EMA 50
- $325.90
- Price above EMA 50
- SMA 200
- $316.88
- Price above SMA 200
- EMA 200
- $324.27
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $330.00
- Average
- $381.33
- High
- $405.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +8.6 | -21.8 | ||||||||||
| 2022 | +2.7 | +3.5 | +9.0 | -3.3 | +3.9 | -5.7 | +1.9 | +0.4 | -8.3 | +12.9 | +9.2 | -3.4 |
| 2023 | +2.8 | -3.4 | +2.3 | +2.8 | +2.0 | +11.5 | -2.1 | -6.9 | +2.9 | +3.4 | +8.6 | +0.6 |
| 2024 | +11.6 | -0.6 | +2.5 | -1.6 | -1.1 | -2.3 | +6.4 | -2.0 | -7.6 | +1.7 | +7.4 | -10.1 |
| 2025 | +13.1 | -0.3 | +8.9 | +5.5 | +0.3 | +2.7 | -3.1 | +1.1 | +6.0 | +8.4 | +8.2 | -6.2 |
| 2026 | +6.0 | +2.4 | -15.7 | -3.0 | -11.4 | +6.9 | +7.9 | +4.9 | -9.3 | +6.8 | +0.5 |



